Browsing Tag
aleniglipron
2 posts
Structure Therapeutics (Nasdaq: GPCR) posts 16% weight loss with oral GLP-1 drug aleniglipron, setting up Phase 3 push
Structure Therapeutics' aleniglipron hits 16% weight loss at 44 weeks in Phase 2, matching injectables. Read the full analysis before Phase 3 begins.
March 16, 2026
Oral GLP-1 race heats up as Structure Therapeutics posts strong ACCESS data for aleniglipron
Find out how Structure Therapeutics’ oral GLP-1 drug aleniglipron delivered double-digit weight loss in the ACCESS trial and what it means for the obesity market.
December 8, 2025